Study S001569

Study GLP111892: Albiglutide Versus Placebo as Add-on to Intensified Basal-Bolus Insulin Therapy in Subjects With Type 2 Diabetes Mellitus

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT02229240
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: WITHDRAWN
Enrollment: 0
Start: 2015-08
Primary completion: 2015-12
Lead sponsor: GlaxoSmithKline
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:Albiglutide; DRUG:Matching albiglutide placebo
Results posted: FALSE

Registered primary outcomes

Percentage of subjects with severe or documented symptomatic hypoglycemia through Week 26 [Up to Week 26]
Change from baseline in glycosylated hemoglobin (HbA1c) at Week 26 [Week 26]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.